


ViaCord Families Cord Blood Use

VIACORD[®]
From PerkinElmer

ViaCord has released **450+** cord blood units for transplant or infusion for regenerative medicine research to over 60 leading medical institutions.¹

A long history in transplant medicine and now the era of regenerative medicine.

4 Million births in the U.S. annually Clinical Cord Blood Applications




How ViaCord Families Have Used Their Cord Blood

Transplant Medicine

- Oncology 14%
- Sickle Cell 14%
- Thalassemia 8%
- Other 10%
- Anemias 4%

Regenerative Medicine

- Cerebral Palsy 25%
- Autism 20%
- Brain Injury / Dysfunction 4%
- Type 1 Diabetes 1%



*Data on file

ViaCord is proud to be trusted by families for over 25 years and recognized by the following organizations and associations:


FDA Registered

AB Accreditation



ViaCord Delivers More Cells

More stem cells provide superior dosing for transplant/infusion.² ViaCord's collection bag contains CPD and was designed to collect and preserve more cells.^{1,3,4} Our collection system provides 33% more TNCs and 58% more CD34+ stem cells.³



The average size of a ViaCord unit released for transplantation is nearly 1 billion TNCs.

Successful transplantation of cord blood stem cells depends primarily on the number of TNCs and CD34+ stem cells collected, processed and cryopreserved. The higher the dose, the greater the chance of transplant success.^{2,5}

Our Innovative Storage Bag

Storing cord blood in multiple compartments gives families more options and flexibility when it comes to using the right amount of cord blood they may need.



Learn more at viacord.com/bagevolution

A Family Shares Their Story

Gracie used her own cord blood in a Phase I Autism & Cord Blood Clinical Trial.



Gracie's story was featured on national tv.

Watch her story at: viacord.com/asd



ViaCord's Newborn Stem Cell Donor Program

ViaCord's Sibling Connection program includes cord blood processing and five years of storage at no cost to expecting parents who have a child in need of a transplant. Any expectant family with a child who has an established diagnosis of a disease that is currently treatable with sibling cord blood may be eligible (the newborn must be a full sibling).

More info at viacord.com/siblingconnection

Better Collections. Better Outcomes.


The goal of every collection, for both cord blood and cord tissue, is to maximize collection volume and minimize contamination. Doing so helps provide the most efficacious unit possible.

The efficacy of a unit impacts treatment outcomes. That's why we've created a helpful tutorial containing tips on how to increase collection volume and minimize contamination.

Topics are broken into chapters so you can easily access and view information as needed.

View our tutorial at: www.viacordcollectiontutorial.com

Newborn Stem Cell Collection Tutorial



ViaCord's Director of Medical and Scientific Affairs, Kate Girard, RN, MSN provides clear instructions for collecting cord blood and cord tissue with the goal of maximizing the number of newborn stem cells with the lowest potential for contamination.

viacord.com | 866-835-0968

Disclaimer: Banking cord blood does not guarantee that treatment will work and only a doctor can determine when it can be used. Cord tissue stem cells are not approved for use in treatment, but research is ongoing.

1. Data on file. 2. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. *N Engl J Med.* 1998;339(22):1565-1577. 3. Kraus M, Foster K, Bridges AR, Walters MC. Cord blood units collected with liquid CPD appear to contain significantly more nucleated and CD34+ cells than units collected with dry heparin. Study conducted by ViaCord. Paper presented at: 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA. Abstract 4227 4. Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Guidance for industry: minimally manipulated, unrelated allogeneic placental/umbilical cord blood intended for hematopoietic reconstitution for specified indications. <http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/lucm187144.pdf>. March 2014. 5. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. *N Engl J Med* 2001;344(24): 1815-1822.

For more details and references visit viacord.com/references. Copyright ©2019 ViaCord, LLC. All rights reserved. Prof-CBSum-0719

Cord Blood Uses

FOR CURRENT TREATMENTS*

All transplant recipients were conditioned with chemotherapy/radiation prior to treatment

Diagnosis	Date of Use	Recipient Age** (yrs)	Donor Relationship	Time Stored** (months)	Cord Volume Collected (mL)	Cell Count (x10 ⁸)
Thalassemia	03/19	6	Sibling	11	80	8.46
Fanconi Anemia/ Acute Myeloid Leukemia	02/19	14	Sibling	4	107	7.25
Severe Aplastic Anemia	02/19	5	Sibling	4	152	19.23
Congenital Hypogammaglobulinemia & Lymphopenia	01/19	4	Sibling	17	100	5.04
Beta Thalassemia Major	11/18	6	Sibling	11	115	10.27
Severe Congenital Neutropenia	11/18	1	Sibling	2	181	13.30
Diamond Blackfan Anemia	11/18	3	Sibling	12	65	2.65
Thalassemia	09/18	9	Sibling	13	141	10.17
Thalassemia	08/18	4	Sibling	22	83	4.92
Sickle Cell Disease	07/18	3	Sibling	10	105	9.78
Chronic Granulomatous Disorder	07/18	8	Sibling	31	150	12.71
Sickle Cell Disease	06/18	8	Sibling	39	88	7.27
Diamond Blackfan Anemia	06/18	4	Sibling	70	68	2.62
Thalassemia	05/18	11	Sibling	16	143	10.56
Sickle Cell Disease	05/18	24	Sibling	54	100	10.47
Sickle Cell Disease	04/18	3	Sibling	14	171	17.89
Acute Myeloid Leukemia	04/18	5	Sibling	9	98	4.83
Sickle Cell Disease	02/18	4	Sibling	7	71	2.14
Sickle Cell Disease	01/18	5	Sibling	25	110	8.79
Acute Myeloid Leukemia	01/18	13	Sibling	157	114	12.12
Thalassemia	11/17	18	Sibling	7	123	8.35
Fanconi Anemia	08/17	6	Sibling	18	95	5.59
Cyclic Neutropenia	08/17	3	Sibling	4	88	4.55
Beta Thalassemia Major	08/17	10	Sibling	7	134	9.14
Sickle Cell Disease	07/17	6	Sibling	34	120	8.03
Severe Aplastic Anemia	06/17	6	Sibling	3	224	17.68
Sickle Cell Disease	06/17	6	Sibling	52	113	8.07
Sickle Cell Disease	05/17	5	Sibling	29	97	5.33
DiGeorge syndrome & severe	04/17	2	Sibling	3	3	22.36
Adrenoleukodystrophy	04/17	8	Sibling	67	172	7.77
Chronic Granulomatous Disease	03/17	5	Sibling	21	121	6.87
Thalassemia	01/17	2	Sibling	9	94	8.37
Fanconi Anemia	01/17	4	Sibling	8	204	18.82



WANT TO LEARN MORE ABOUT OUR SIBLING DONOR PROGRAM AND HOW CORD BLOOD CAN BE USED? TALK TO A VIACORD REPRESENTATIVE OR VISIT US ONLINE.

viacord.com | 866-835-0968

FOR CURRENT TREATMENTS*

All transplant recipients were conditioned with chemotherapy/radiation prior to treatment

Diagnosis	Date of Use	Recipient Age** (yrs)	Donor Relationship	Time Stored** (months)	Cord Volume Collected (mL)	Cell Count (x10 ⁸)
Sickle Cell Disease	12/16	12	Sibling	31	107	10.20
Sickle Cell Disease	11/16	4	Sibling	13	106	5.82
Diamond Blackfan Anemia	09/16	11	Sibling	76	63	2.64
Acute Myelogenous Leukemia	08/16	3	Sibling	3	152	15.81
Thalassemia	08/16	11	Sibling	20	134	9.49
Thalassemia	07/16	4	Sibling	9	93	6.81
Juvenile myelomonocytic leukemia (JMML)	05/16	2	Sibling	1	70	2.65
Severe Congenital Neutropenia	02/16	16	Sibling	39	91	5.85
Diamond Blackfan Anemia	11/15	4	Sibling	28	140	10.88
Sickle Cell Disease	11/15	12	Sibling	13	117	8.60
Thalassemia	10/15	6	Sibling	15	89	7.08
Severe Congenital Neutropenia	08/15	4	Sibling	14	103	6.07
Sickle Cell Disease	07/15	14	Sibling	45	121	8.33
Sickle Cell Disease	05/15	4	Sibling	14	92	6.36
Diamond Blackfan Anemia	04/15	5	Sibling	17	139	10.43
Sickle Cell	04/15	8	Sibling	32	77	4.24
Thalassemia	04/15	5	Sibling	12	114	7.05
Acute Lymphoblastic Leukemia	04/15	9	Sibling	23	90	5.95
Acute Lymphoblastic Leukemia	04/15	6	Sibling	45	115	6.46
Acute Myeloid Leukemia	04/15	2	Self	21	89	8.86
Acute Lymphoblastic Leukemia	01/15	4	Sibling	1	82	5.68
Sickle Cell Disease	08/14	8	Sibling	86	118	12.48
Sickle Cell Disease	08/14	8	Sibling	86	70	5.20
Acute Myelogenous Leukemia	05/14	4	Sibling	11	95	6.58
SCIDS-Adenosine Deaminase Deficiency	04/14	1	Sibling	4	77	6.08
Sickle Cell Disease	04/14	11	Sibling	87	86	2.97
Sickle Cell Disease	04/14	3	Sibling	7	136	8.63
Leukemia	03/14	3	Sibling	21	122	7.96
Sickle Cell Disease	02/14	3	Sibling	20	125	8.14
Chronic Myelogenous Leukemia	01/14	6	Sibling	9	106	6.16
Sickle Cell Disease	08/13	9	Sibling	56	72	5.69
Sickle Cell Disease	07/13	11	Sibling	29	97	6.46
Thalassemia	06/13	8	Sibling	16	134	13.40
Fanconi Anemia	05/13	9	Sibling	3	80	5.49
Chronic Granulomatous Disease	03/13	9	Sibling	13	97	4.83
Wiskott-Aldrich Syndrome	02/13	4	Sibling	18	113	6.56
Diamond Blackfan Anemia	02/13	4	Sibling	20	81	3.85
Juvenile Myelomonocytic Leukemia	01/13	4	Sibling	2	133	10.66
Thalassemia	09/12	3	Sibling	13	55	2.81
Acute Myelogenous Leukemia	07/12	3	Sibling	4	95	7.06

FOR CURRENT TREATMENTS*

All transplant recipients were conditioned with chemotherapy/radiation prior to treatment

Diagnosis	Date of Use	Recipient Age** (yrs)	Donor Relationship	Time Stored** (months)	Cord Volume Collected (mL)	Cell Count (x10 ⁸)
Diamond-Blackfan Anemia	06/12	6	Sibling	16	129	12.95
Beta Thalassemia	04/12	6	Sibling	33	146	15.65
Sickle Cell Disease	03/12	12	Sibling	101	157	22.24
Sickle Cell Disease	03/12	3	Sibling	15	131	20.10
Sickle Cell Disease	03/12	8	Sibling	24	57	1.68
Acute Myelogenous Leukemia	02/12	3	Sibling	8	106	5.23
Aplastic Anemia	02/12	12	Sibling	19	86	5.64
Fanconi Anemia	01/12	6	Sibling	7	93	4.83
Fanconi Anemia	01/12	6	Sibling	11	128	6.27
Hemophagocytic Lymphohistiocytosis	11/11	9	Self	105	91	5.40
Thalassemia	08/11	8	Sibling	15	100	4.32
Thalassemia	07/11	14	Sibling	22	103	11.78
E Beta Thalassemia	05/11	7	Sibling	26	89	6.19
Acute Myeloid Leukemia	05/11	2	Sibling	2	78	2.86
Sickle Cell Disease	03/11	8	Sibling	15	100	4.32
Acute Lymphoblastic Leukemia	03/11	7	Sibling	27	127	8.57
Sickle Cell Disease	03/11	10	Sibling	18	117	9.34
Sickle Cell Disease	02/11	7	Sibling	26	114	6.40
Acute Myeloid Leukemia	09/10	4	Sibling	15	141	11.05
Aplastic Anemia	09/10	4	Sibling	49	109	12.17
Sickle Cell Disease	09/10	4	Sibling	9	51	2.92
Sickle Cell Disease	09/10	5	Sibling	9	111	7.50
Acute Lymphoblastic Leukemia	08/10	4	Sibling	5	71	6.53
Sickle Cell Disease	07/10	6	Sibling	24	104	9.84
Cartilage-Hair Hypoplasia	07/10	2	Sibling	10	134	11.58
Myelodysplastic Syndrome	05/10	4	Self	42	74	5.57
Thalassemia	03/10	6	Sibling	9	136	15.55
Acute Lymphoblastic Lymphoma	12/09	5	Sibling	4	91	3.63
Sickle Cell Disease	11/09	10	Sibling	47	112	9.60
Acute Myeloid Leukemia	10/09	2	Sibling	4	141	12.73
Acute Lymphoblastic Leukemia	08/09	3	Sibling	3	135	13.08
Sickle Cell Disease	07/09	6	Sibling	6	134	8.76
Chronic Granulomatous Disease	07/09	5	Sibling	12	110	8.65
Sickle Cell Disease	07/09	9	Sibling	11	86	2.88
Sickle Cell Disease	06/09	6	Sibling	6	101	5.92
Sickle Cell Disease	06/09	6	Sibling	46	173	30.94
Sickle Cell Disease	04/09	8	Sibling	43	139	13.65
Fanconi Anemia	04/09	5	Sibling	19	104	7.28
Severe Aplastic Anemia	01/09	5	Self	54	107	6.81
Non-Hodgkin's Lymphoma	12/08	7	Sibling	42	123	7.75

FOR CURRENT TREATMENTS*

All transplant recipients were conditioned with chemotherapy/radiation prior to treatment

Diagnosis	Date of Use	Recipient Age** (yrs)	Donor Relationship	Time Stored** (months)	Cord Volume Collected (mL)	Cell Count (x10 ⁸)
Primitive Neuronal Tumor	12/08	1	Self	9	70	4.92
Acute Lymphoblastic Leukemia	12/08	10	Sibling	4	140	9.55
Acute Lymphoblastic Leukemia	08/08	6	Sibling	23	134	12.80
Sickle Cell Disease	08/08	9	Sibling	91	93	9.56
Acute Myelogenous Leukemia	07/08	2	Sibling	2	80	3.80
Sickle Cell Disease	07/08	2	Sibling	7	76	3.82
Thalassemia	05/08	2	Sibling	96	133	30.00
Thalassemia	05/08	5	Sibling	7	124	14.04
Acute Lymphoblastic Leukemia	01/08	3	Sibling	9	138	11.70
Thalassemia	12/07	9	Sibling	14	130	10.18
Fanconi Anemia	10/07	3	Sibling	9	98	7.64
Sickle Cell Disease	10/07	10	Sibling	29	97	10.65
Sickle Cell Disease	09/07	1	Sibling	2	197	14.66
Sickle Cell Disease	09/07	3	Sibling	14	121	8.93
Chronic Granulomatous Disease	06/07	5	Sibling	9	88	7.35
Acute Lymphoblastic Leukemia	06/07	6	Sibling	3	154	12.32
Severe Aplastic Anemia	06/07	4	Sibling	4	141	15.20
Severe Combined Immunodeficiency	06/07	6	Sibling	8	108	6.70
Acute Lymphoblastic Leukemia	05/07	6	Sibling	39	151	16.56
Sickle Cell Disease	04/07	10	Sibling	24	112	7.42
Acute Lymphoblastic Leukemia	04/07	7	Sibling	22	71	4.37
Brain Cancer	03/07	11 months	Self	11	58	2.65
Acute Lymphoblastic Leukemia	03/07	7	Sibling	39	132	16.70
Thalassemia	02/07	3	Sibling	13	105	11.22
Severe Congenital Neutropenia	02/07	4	Sibling	29	76	3.08
Acute Myelogenous Leukemia	01/07	8	Sibling	38	66	2.77
Sickle Cell Disease	01/07	14	Sibling	22	92	7.30
Sickle Cell Disease	01/07	7	Sibling	21	127	7.77
Acute Myelogenous Leukemia	12/06	3	Sibling	3	83	6.58
Acute Myelogenous Leukemia	10/06	3	Sibling	1	117	7.70
Sickle Cell Disease	09/06	5	Sibling	24	101	11.74
Thalassemia	08/06	6	Sibling	18	109	14.77
Sickle Cell Disease	06/06	11	Sibling	15	119	11.66
Sickle Cell Disease	05/06	8	Sibling	55	120	9.80
Shwachman-Diamond Anemia	05/06	7	Sibling	13	86	5.61
Acute Lymphoblastic Leukemia	05/06	13	Sibling	50	126	12.66
Lymphoma	04/06	3	Sibling	35	124	22.45
Thalassemia	03/06	6	Sibling	23	111	8.42
Myelodysplastic Syndrome	03/06	5	Sibling	7	121	9.09
Acute Lymphoblastic Leukemia	01/06	5	Sibling	2	154	16.66
Severe Aplastic Anemia	12/05	7	Sibling	10	83	7.70

FOR CURRENT TREATMENTS*

All transplant recipients were conditioned with chemotherapy/radiation prior to treatment

Diagnosis	Date of Use	Recipient Age** (yrs)	Donor Relationship	Time Stored** (months)	Cord Volume Collected (mL)	Cell Count (x10 ⁸)
Sickle Cell Disease	10/05	12	Sibling	57	172	18.80
Adrenoleukodystrophy	10/05	4	Sibling	39	95	6.96
Sickle Cell Disease	09/05	11	Sibling	12	85	3.42
Thalassemia	09/05	5	Sibling	8	175	26.80
Sickle Cell Disease	07/05	8	Sibling	13	99	9.48
Thalassemia	07/05	9	Sibling	14	120	5.02
Acute Lymphoblastic Leukemia	06/05	3	Sibling	8	105	15.32
Acute Myelogenous Leukemia	05/05	3	Sibling	2	100	9.28
Acute Myelogenous Leukemia	03/05	4	Sibling	28	115	6.86
Severe Congenital Neutropenia	03/05	5	Sibling	13	110	18.10
Kostmann's Syndrome	03/05	3	Sibling	8	154	5.95
Fanconi Anemia	01/05	8	Sibling	7	88	3.15
Thalassemia	01/05	4	Sibling	8	144	15.14
Thalassemia	01/05	4	Sibling	22	96	7.30
Thalassemia	12/04	6	Sibling	16	137	8.22
Thalassemia	12/04	5	Sibling	25	106	9.64
Thalassemia	11/04	15	Sibling	37	81	8.30
NEMO Deficiency	10/04	5	Sibling	7	136	9.65
Thalassemia	09/04	9	Sibling	6	127	13.32
Thalassemia	08/04	8	Sibling	26	84	5.10
Acute Myelogenous Leukemia	02/04	2	Sibling	4	149	10.81
Sickle Cell Disease	01/04	2	Sibling	7	80	3.04
Acute Lymphoblastic Leukemia	12/03	3	Sibling	12	157	16.58
Thalassemia	12/03	5	Sibling	9	112	8.25
Hurler Syndrome	11/03	2	Sibling	5	78	2.76
Wiskott-Aldrich Syndrome	10/03	2	Sibling	2	78	9.08
Acute Lymphoblastic Leukemia	09/03	8	Sibling	17	99	9.85
Fanconi Anemia	08/03	5	Sibling	80	129	6.90
Acute Lymphoblastic Leukemia	08/03	6	Sibling	44	97	4.00
Diamond-Blackfan Anemia	08/03	7	Sibling	14	102	6.93
Sickle Cell Disease	06/03	9	Sibling	8	120	16.50
Acute Lymphoblastic Leukemia	06/03	3	Sibling	21	96	6.20
Severe Aplastic Anemia	05/03	2	Sibling	3	109	10.51
Acute Lymphoblastic Leukemia	05/03	3	Sibling	2	134	22.32
Thalassemia	05/03	7	Sibling	8	83	5.83
Acute Myelogenous Leukemia	03/03	5	Sibling	2	187	17.41
Acute Lymphoblastic Leukemia	01/03	7	Sibling	29	103	13.10
Myelodysplastic Syndrome	01/03	6	Sibling	8	135	12.82
Acute Myelogenous Leukemia	12/02	2	Sibling	3	86	7.42
Acute Lymphoblastic Leukemia	11/02	4	Sibling	4	79	15.39

FOR CURRENT TREATMENTS*

All transplant recipients were conditioned with chemotherapy/radiation prior to treatment

Diagnosis	Date of Use	Recipient Age** (yrs)	Donor Relationship	Time Stored** (months)	Cord Volume Collected (mL)	Cell Count (x10 ⁸)
Sickle Cell Disease	10/02	5	Sibling	18	95	7.00
Immune Dysregulation, Polyendocrinopathy,	09/02	2	Sibling	6	93	7.63
Acute Myelogenous Leukemia	08/02	4	Sibling	22	109	4.40
Acute Myelogenous Leukemia	07/02	4	Sibling	3	157	11.54
Sickle Cell Disease	07/02	6	Sibling	13	72	5.40
Acute Myelogenous Leukemia	06/02	2	Sibling	1	257	25.14
Chronic Granulomatous Disease	04/02	6	Sibling	13	98	7.20
Fanconi Anemia	04/02	3	Sibling	16	49	1.10
Thalassemia	02/02	2	Sibling	13	147	17.80
Acute Lymphoblastic Leukemia	01/02	5	Sibling	5	98	5.00
Neuroblastoma	12/01	6	Self	67	67	4.10
Sickle Cell Disease	12/01	14	Sibling	32	81	9.00
Thalassemia	11/01	7	Sibling	8	73	6.90
Sickle Cell Disease	11/01	7	Sibling	20	133	7.80
Acute Lymphoblastic Leukemia	07/01	6	Sibling	17	112	9.40
Severe Aplastic Anemia	06/01	10	Sibling	39	122	10.80
Severe Aplastic Anemia	04/01	2	Self	20	137	14.10
Thalassemia	12/00	4	Sibling	23	81	6.20
Thalassemia	12/00	3	Sibling	11	78	5.00
Acute Myelogenous Leukemia	11/00	3	Sibling	4	113	10.70
Severe Aplastic Anemia	10/00	13	Sibling	13	96	7.32
Thalassemia	10/00	4	Sibling	13	114	13.00
Sickle Cell Disease	07/00	4	Sibling	25	122	4.00
Thalassemia	06/00	4	Sibling	16	101	11.00
Sickle Cell Disease	05/00	10	Sibling	8	132	15.00
Sickle Cell Disease	02/00	8	Sibling	23	140	10.60
SCID/Myelodysplastic Syndrome	09/99	7	Sibling	7	117	18.00
Sickle Cell Disease	09/99	2	Sibling	9	134	10.80
Fanconi Anemia	06/99	4	Sibling	6	148	15.10
Thalassemia	12/98	2	Sibling	7	99	9.00
Thalassemia	06/98	4	Sibling	6	110	8.40
Acute Myelogenous Leukemia	12/97	4	Sibling	<1	94	7.10
Wiskott-Aldrich Syndrome	11/97	3	Sibling	4	193	14.20
Severe Aplastic Anemia	09/97	3	Sibling	9	59	1.27
Acute Lymphoblastic Leukemia	06/96	8	Sibling	2	95	7.40

REGENERATIVE MEDICINE***

Conditions listed below are being studied subject to FDA-approved Clinical Trials

Diagnosis	Date of Use	Recipient Age** (yrs)	Donor Relationship	Time Stored** (months)	Cord Volume Collected (mL)	Cell Count (x10 ⁸)
Autism Spectrum Disorder	03/19	6	Self	71	95	8.62
Autism Spectrum Disorder	03/19	5	Self	63	83	5.10
Cerebral Palsy	03/19	2	Sibling	19	97	3.83
Cerebral Palsy	03/19	10	Sibling	116	115	5.85
Cerebral Palsy	03/19	4	Self	52	153	24.59
Cerebral Palsy	03/19	2	Sibling	68	90	5.70
Apraxia	02/19	4	Self	46	131	13.85
Autism Spectrum Disorder	02/19	4	Self	164	124	10.77
Autism Spectrum Disorder	02/19	10	Sibling	30	127	13.44
Autism Spectrum Disorder	02/19	8	Sibling	30	127	13.44
Cerebral Palsy	01/19	5	Self	57	84	3.98
Autism Spectrum Disorder	01/19	9	Self	103	97	7.33
Autism Spectrum Disorder	12/18	8	Sibling	115	112	10.48
Autism Spectrum Disorder	12/18	7	Self	90	93	8.76
Hydrocephalus	11/18	0.4	Self	4	100	5.02
Autism Spectrum Disorder	11/18	5	Self	64	96	5.48
Autism Spectrum Disorder	11/18	6	Self	76	93	4.01
Autism Spectrum Disorder	10/18	4	Self	49	63	3.91
Autism Spectrum Disorder	10/18	5	Self	62	72	4.01
Autism Spectrum Disorder	10/18	3	Self	40	105	11.57
Autism Spectrum Disorder	10/18	6	Sibling	56	74	6.79
Autism Spectrum Disorder	09/18	8	Sibling	84	70	5.49
Autism Spectrum Disorder	09/18	11	Self	136	137	19.09
Autism Spectrum Disorder	09/18	9	Self	109	123	5.64
Autism Spectrum Disorder	09/18	9	Self	119	246	13.74
Autism Spectrum Disorder & Cerebral Palsy	09/18	3	Sibling	13	77	4.89
Autism Spectrum Disorder	08/18	5	Self	62	94	3.48
Cerebral Palsy	08/18	5	Sibling	40	111	7.82
Autism Spectrum Disorder	08/18	4	Self	48	66	4.27
Cerebral Palsy	06/18	4	Sibling	18	107	8.88
Autism Spectrum Disorder	06/18	13	Self	164	103	7.83
Autism Spectrum Disorder	05/18	4	Self	49	144	7.78
Apraxia	05/18	4	Self	52	84	4.75
Autism Spectrum Disorder	04/18	9	Self	111	81	6.42
Hydrocephalus	03/18	<1	Self	3	98	5.41
Autism Spectrum Disorder & Cerebral Palsy	03/18	3	Sibling	13	105	8.85
Autism Spectrum Disorder	02/18	5	Self	70	107	7.49
Autism Spectrum Disorder	02/18	4	Self	59	143	12.40
Autism Spectrum Disorder	02/18	6	Self	81	115	5.93

REGENERATIVE MEDICINE***

Conditions listed below are being studied subject to FDA-approved Clinical Trials

Diagnosis	Date of Use	Recipient Age** (yrs)	Donor Relationship	Time Stored** (months)	Cord Volume Collected (mL)	Cell Count (x10 ⁸)
Autism Spectrum Disorder	02/18	6	Self	73	97	9.02
Autism Spectrum Disorder	02/18	8	Sibling	56	97	7.15
Autism Spectrum Disorder	02/18	6	Self	81	92	5
Autism Spectrum Disorder	01/18	7	Self	86	107	10.97
Autism Spectrum Disorder	01/18	7	Self	79	78	5.15
Cerebral Palsy	12/17	4	Sibling	46	63	2.44
Autism Spectrum Disorder	12/17	5	Self	61	100	10.28
Autism Spectrum Disorder	12/17	7	Self	87	114	10.61
Autism Spectrum Disorder	11/17	4	Self	51	168	24.57
Autism Spectrum Disorder	11/17	7	Self	85	142	21.90
Autism Spectrum Disorder	11/17	7	Self	92	91	7.72
Autism Spectrum Disorder	11/17	5	Self	59	83	7.18
Autism Spectrum Disorder	10/17	7	Self	87	111	5.72
Autism Spectrum Disorder	10/17	8	Self	93	120	9.93
Apraxia	10/17	8	Self	91	79	3.28
Autism Spectrum Disorder	10/17	6	Self	65	131	9.15
Autism Spectrum Disorder	10/17	6	Self	65	153	12.89
Autism Spectrum Disorder	10/17	7	Self	84	91	6.88
Autism Spectrum Disorder	10/17	7	Self	85	109	14.53
Autism Spectrum Disorder	10/17	6	Self	74	106	7.12
Hydrocephalus	10/17	4	Self	48	80	3.69
Autism Spectrum Disorder	09/17	7	Self	86	194	18.15
Autism Spectrum Disorder	09/17	4	Self	52	104	13.08
Autism Spectrum Disorder	09/17	5	Self	64	117	12.59
Autism Spectrum Disorder	09/17	4	Self	53	99	8.35
Autism Spectrum Disorder	09/17	6	Self	72	103	7.77
Autism Spectrum Disorder	08/17	5	Self	63	85	8.97
Autism Spectrum Disorder	08/17	8	Self	96	112	8.15
Autism Spectrum Disorder	08/17	5	Self	55	85	6.05
Autism Spectrum Disorder	07/17	6	Self	80	103	7.57
Autism Spectrum Disorder	07/17	5	Self	70	86	9.93
Autism Spectrum Disorder	06/17	6	Self	84	107	16.66
Autism Spectrum Disorder	06/17	6	Self	79	90	6.02
Autism Spectrum Disorder	05/17	5	Self	57	113	13.98
Autism Spectrum Disorder	04/17	7	Self	87	79	3.84
Autism Spectrum Disorder	04/17	4	Self	52	133	19.22
Cerebral Palsy	04/17	4	Self	54	162	15.82
Apraxia	03/17	2	Self	30	105	16.00
Autism Spectrum Disorder	03/17	7	Self	80	109	9.94
Autism Spectrum Disorder	03/17	5	Self	65	89	6.24

REGENERATIVE MEDICINE***

Conditions listed below are being studied subject to FDA-approved Clinical Trials

Diagnosis	Date of Use	Recipient Age** (yrs)	Donor Relationship	Time Stored** (months)	Cord Volume Collected (mL)	Cell Count (x10 ⁸)
Autism Spectrum Disorder	02/17	8	Self	104	105	8.33
Cerebral Palsy	01/17	5	Self	54	107	10.58
Autism Spectrum Disorder	01/17	7	Self	82	104	8.24
Autism Spectrum Disorder	01/17	5	Self	62	135	14.64
Autism Spectrum Disorder	01/17	7	Self	86	90	5.57
Autism Spectrum Disorder	12/16	7	Self	82	101	9.36
Autism Spectrum Disorder	11/16	8	Self	96	118	12.41
Autism Spectrum Disorder	11/16	6	Self	76	137	15.13
Autism Spectrum Disorder	10/16	6	Self	76	131	13.00
Autism Spectrum Disorder	10/16	4	Self	51	91	5.88
Autism Spectrum Disorder	10/16	4	Self	67	119	5.85
Autism Spectrum Disorder	10/16	3	Self	37	100	6.65
Autism Spectrum Disorder	09/16	5	Self	71	102	5.14
Autism Spectrum Disorder	09/16	8	Self	95	126	10.56
Autism Spectrum Disorder	09/16	3	Self	46	225	19.37
Autism Spectrum Disorder	09/16	8	Self	95	100	9.14
Autism Spectrum Disorder	06/16	<1	Self	11	66	6.40
Apraxia	03/16	5	Self	69	100	10.20
Cerebral Palsy	03/16	1	Sibling	60	124	6.28
Cerebral Palsy	03/16	4	Sibling	7	103	9.26
Cerebral Palsy	03/16	2	Sibling	4	109	7.24
Apraxia	03/16	4	Self	56	140	13.38
Cerebral Palsy	03/16	5	Sibling	42	101	8.47
Apraxia	02/16	8	Self	98	68	2.29
Apraxia	01/16	7	Self	95	75	3.75
Cerebral Palsy	12/15	3	Sibling	9	142	8.92
Cerebral Palsy	09/15	<1	Self	9	109	4.45
Obstructive Hydrocephalus, Nystgamus and Cerebral Palsy	08/15	<1	Self	10	90	2.24
Cerebral Palsy	07/15	4	Self	52	81	5.59
Cerebral Palsy	01/15	5	Self	51	122	11.03
Cerebral Palsy	01/15	1	Self	10	100	8.40
Autism Spectrum Disorder	12/14	6	Self	61	105	8.57
Autism Spectrum Disorder	12/14	4	Self	42	89	4.73
Autism Spectrum Disorder	11/14	5	Self	65	63	2.76
Autism Spectrum Disorder	11/14	4	Self	56	124	17.68
Autism Spectrum Disorder	11/14	5	Self	65	121	12.09
Autism Spectrum Disorder	11/14	3	Self	35	73	3.87
Cerebral Palsy	10/14	10	Self	124	98	7.87
Autism Spectrum Disorder	10/14	5	Self	64	73	4.50

REGENERATIVE MEDICINE***

Conditions listed below are being studied subject to FDA-approved Clinical Trials

Diagnosis	Date of Use	Recipient Age** (yrs)	Donor Relationship	Time Stored** (months)	Cord Volume Collected (mL)	Cell Count (x10 ⁸)
Autism Spectrum Disorder	10/14	5	Self	61	165	20.77
Cerebral Palsy	10/14	5	Self	58	104	3.75
Autism Spectrum Disorder	09/14	6	Self	67	96	5.30
Cerebral Palsy	09/14	2	Self	27	57	1.73
Autism Spectrum Disorder	08/14	5	Self	55	101	7.06
Autism Spectrum Disorder	07/14	3	Self	33	110	7.63
Autism Spectrum Disorder	07/14	6	Self	69	120	9.72
Hydrocephalus	04/14	3	Self	31	96	7.63
Cerebral Palsy	04/14	2	Self	21	134	7.63
Stroke	12/13	6	Self	76	108	3.93
Cerebral Palsy	09/13	7 months	Self	8	77	4.50
Cerebral Palsy	07/13	4	Self	48	102	5.18
Cerebral Palsy	05/13	5	Self	60	97	4.97
Cerebral Palsy	03/13	1	Self	12	77	21.32
Hydrocephalus	03/13	4 months	Self	4	110	6.86
Cerebral Palsy	02/13	3	Self	34	87	4.18
Cerebral Palsy	01/13	3	Self	30	58	1.63
Cerebral Palsy	01/13	4	Self	53	110	7.60
Septic Brain Injury	11/12	7 months	Self	7	101	7.42
Cerebral Palsy	11/12	7	Self	83	78	4.88
Cerebral Palsy	10/12	1	Self	16	78	7.83
Cerebral Palsy	07/12	3	Self	34	87	7.70
Cerebral Palsy	06/12	2	Self	23	64	5.10
Cerebral Palsy	06/12	6	Self	73	175	19.35
Cerebral Palsy	04/12	1	Self	17	66	8.09
Cerebral Palsy	04/12	2	Self	22	61	3.22
Cerebral Palsy	03/12	3	Self	35	150	8.24
Cerebral Palsy	03/12	2	Self	21	52	1.78
Cerebral Palsy	02/12	1	Self	11	44	1.22
Cerebral Palsy	01/12	4	Self	51	73	3.04
Cerebral Palsy	12/11	1	Self	16	64	4.32
Cerebral Palsy	11/11	4	Self	43	108	14.16
Cerebral Palsy	09/11	3	Self	35	85	7.12
Cerebral Palsy	09/11	4	Self	44	104	5.24
Cerebral Palsy	09/11	3	Self	34	118	6.48
Hydrocephalus	09/11	0	Self	3	109	5.83
Cerebral Palsy	08/11	3	Self	30	63	3.10
Cerebral Palsy	08/11	5	Self	58	109	7.75
Cerebral Palsy	07/11	5	Self	54	56	1.20
Cerebral Palsy	05/11	1	Self	8	76	3.13
Cerebral Palsy	04/11	6	Self	73	100	4.04

REGENERATIVE MEDICINE***

Conditions listed below are being studied subject to FDA-approved Clinical Trials

Diagnosis	Date of Use	Recipient Age** (yrs)	Donor Relationship	Time Stored** (months)	Cord Volume Collected (mL)	Cell Count (x10 ⁸)
Cerebral Palsy	04/11	1	Self	10	59	2.00
Cerebral Palsy	04/11	3	Self	37	102	7.37
Cerebral Palsy	01/11	1	Self	16	64	9.82
Cerebral Palsy	01/11	2	Self	27	110	11.60
Cerebral Palsy	01/11	2	Self	25	90	2.93
Type 1 Diabetes	12/10	10	Self	116	108	6.00
Cerebral Palsy	12/10	4	Self	52	72	5.00
Cerebral Palsy	11/10	2	Self	25	88	6.50
Cerebral Palsy	11/10	4	Self	48	85	2.46
Cerebral Palsy	11/10	1	Self	14	70	1.91
Cerebral Palsy	11/10	2 months	Self	2	57	1.90
Cerebral Palsy	10/10	5	Self	61	134	8.23
Cerebral Palsy	08/10	8	Self	100	126	10.50
Cerebral Palsy	07/10	1	Self	13	112	5.20
Cerebral Palsy	06/10	2	Self	27	68	2.09
Cerebral Palsy	06/10	1	Self	7	59	7.41
Hydrocephalus	05/10	2 months	Self	2	59	1.93
Cerebral Palsy	02/10	1	Self	13	119	8.98
Cerebral Palsy	01/10	3	Self	40	121	10.14
Cerebral Palsy	01/10	8	Self	95	76	6.40
Cerebral Palsy	01/10	4	Self	46	126	13.78
Type 1 Diabetes	12/09	7	Self	83	58	3.70
Cerebral Palsy	12/09	2	Self	27	59	1.98
Cerebral Palsy	11/09	3	Self	39	84	3.20
Cerebral Palsy	11/09	3	Self	35	77	8.35
Cerebral Palsy	11/09	5	Self	53	98	6.44
Cerebral Palsy	10/09	1	Self	17	65	4.96
Cerebral Palsy	10/09	4	Self	50	81	2.66
Cerebral Palsy	09/09	3	Self	31	158	11.88
Cerebral Palsy	09/09	4	Self	48	175	17.23
Type 1 Diabetes	09/09	7	Self	77	104	6.60
Cerebral Palsy	09/09	4	Self	42	110	10.78
Cerebral Palsy	09/09	3	Self	32	115	7.49
Cerebral Palsy	09/09	3	Self	31	47	2.76
Cerebral Palsy	07/09	2	Self	24	97	12.84
Cerebral Palsy	07/09	5	Self	57	52	3.23
Cerebral Palsy	07/09	4	Self	44	86	5.40
Cerebral Palsy	06/09	3	Self	32	124	16.64
Cerebral Palsy	06/09	3	Self	31	48	1.80
Cerebral Palsy	06/09	2	Self	21	105	5.90
Cerebral Palsy	05/09	4	Self	52	111	7.57

REGENERATIVE MEDICINE***

Conditions listed below are being studied subject to FDA-approved Clinical Trials

Diagnosis	Date of Use	Recipient Age** (yrs)	Donor Relationship	Time Stored** (months)	Cord Volume Collected (mL)	Cell Count (x10 ⁹)
Cerebral Palsy	04/09	8 months	Self	8	126	7.78
Cerebral Palsy	04/09	3	Self	34	60	2.48
Cerebral Palsy	04/09	4	Self	33	101	9.15
Cerebral Palsy	03/09	5	Self	58	118	5.92
Cerebral Palsy	03/09	8	Self	93	89	6.20
Cerebral Palsy	03/09	2	Self	23	95	5.18
Cerebral Palsy	02/09	1	Self	13	137	12.71
Cerebral Palsy	02/09	7	Self	79	86	5.20
Cerebral Palsy	02/09	9	Self	107	51	12.20
Cerebral Palsy	02/09	4	Self	47	80	2.09
Cerebral Palsy	02/09	7	Self	81	51	15.40
Cerebral Palsy	01/09	6	Self	71	126	10.10
Cerebral Palsy	01/09	4	Self	44	88	5.00
Cerebral Palsy	01/09	3	Self	38	101	8.83
Cerebral Palsy	12/08	4	Self	46	84	2.95
Cerebral Palsy	12/08	2	Self	27	76	3.45
Cerebral Palsy	12/08	3	Self	40	92	5.42
Cerebral Palsy	11/08	4	Self	44	80	3.07
Cerebral Palsy	09/08	1	Self	16	124	6.58
Cerebral Palsy	09/08	1	Self	16	69	3.48
Type 1 Diabetes	08/08	5	Self	64	86	5.16
Cerebral Palsy	08/08	6	Self	73	131	8.38
Cerebral Palsy	07/08	8 months	Self	8	58	5.81
Cerebral Palsy	07/08	2	Self	21	55	2.02
Cerebral Palsy	07/08	2	Self	23	119	9.70
Traumatic Brain Injury	06/08	4	Self	44	76	2.96
Traumatic Brain Injury	06/08	4	Self	44	134	7.57
Type 1 Diabetes	03/07	10	Self	124	82	6.10
Dysgenesis of the Corpus Callosum	03/07	1	Self	17	133	13.97

This is intended for educational/marketing purposes only and should not be used or interpreted as information on treatments or diagnoses.

*Banking cord blood does not guarantee that treatment will work and only a doctor can determine when it can be used.

**The recipient age and time stored have been rounded to the nearest whole number.

***Cord blood research to treat these conditions is experimental. These diseases are currently not considered treatable with cord blood and may never be considered effective in treating such conditions.

**WANT TO LEARN MORE ABOUT REGENERATIVE MEDICINE AND POTENTIAL NEW USES FOR CORD BLOOD? TALK TO A VIACORD REPRESENTATIVE OR VISIT US ONLINE.
www.viacord.com | 866-835-0968**



For more details and references visit www.viacord.com/references.

Con-TX-0819